Cytarabine

Cytarabine

SCHEMBL4938656

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2

The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.71
MTOR P42345 2/20 0.71
THRB P10828 1/20 0.71
MDM2 Q00987 1/20 0.71
NCOA1 Q15788 1/20 0.71
NCOA3 Q9Y6Q9 1/20 0.71
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.48
GMNN O75496 1/20 0.48
TP53 P04637 1/20 0.48
NFKB1 P19838 1/20 0.48
DNMT1 P26358 1/20 0.48
THPO P40225 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
BLM P54132 1/20 0.48
HBB P68871 1/20 0.48
PMP22 Q01453 1/20 0.48
NT5E P21589 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cytidine SCHEMBL28043130 0.86 LMNA (0.70) LMNAMTORTHRBMDM2NCOA1
Cytidine SCHEMBL21381484 0.85 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
Cytidine SCHEMBL27706521 0.85 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
Cytidine SCHEMBL21381483 0.85 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
Cytidine SCHEMBL28281290 0.85 LMNA (0.71) LMNAMTORTHRBMDM2NCOA1
Cytarabine SCHEMBL23066241 0.84 LMNA (1.00) LMNAMTORTHRBMDM2NCOA1
Cytarabine SCHEMBL17993618 0.84 LMNA (1.00) LMNAMTORTHRBMDM2NCOA1
Cytarabine SCHEMBL172274 0.84 LMNA (1.00) LMNAMTORTHRBMDM2NCOA1
Cytarabine SCHEMBL20546595 0.84 LMNA (1.00) LMNAMTORTHRBMDM2NCOA1
Cytarabine SCHEMBL12202579 0.84 LMNA (1.00) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103110-A1 Compounds DRUG DISCOVERY LABORATORY AS (NO) 2008-05-01 US disclosed
EP-1804838-A2 DRUG CONJUGATES OF LONG CHAIN FATTY ACID OR ESTER MOIETIES AS PROTEIN BINDING PRODRUGS Drug Discovery Laboratory AS (NO) 2007-07-11 EP disclosed
WO-2006030217-A2 DRUG CONJUGATES OF LONG CHAIN FATTY ACID OR ESTER MOIETIES AS PROTEIN BINDING PRODRUGS DRUG DISCOVERY LABORATORY AS (NO) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103110-A1 Compounds ATIC, CDA, PAICS LMNA 2537/4885MTOR 4154/4885THRB 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.